Zimmer Biomet Holdings, Inc., commonly referred to as ZBH, is a global leader in the medical device industry. Founded in 1927 and headquartered in Warsaw, Indiana, ZBH specializes in designing, manufacturing, and marketing a wide portfolio of orthopedic reconstructive products, spine and trauma devices, dental implants, and related surgical products.
ZBH derives its strength from its commitment to innovation, collaborative relationships, and extensive knowledge in the fields of orthopedics, neurology, and spine care. Its mission is committed to alleviating pain and improving the quality of life for people around the world by providing advanced medical solutions. The company continuously invests in research and development to create leading-edge technologies, innovative products, and comprehensive solutions to address the evolving needs of patients, surgeons, and healthcare providers.
Over its history, ZBH has achieved significant growth and expansion. Today, it operates in over 25 countries worldwide, serving tens of thousands of healthcare institutions and millions of patients annually. With more than 10,000 employees, ZBH remains committed to its core purpose of restoring mobility, alleviating pain, and improving the quality of life for patients around the world.
The product portfolio of ZBH encompasses joint reconstruction, sports medicine, extremities and trauma, spinal and bone fixing devices, dental implants, and related surgical products. Using advanced materials and technologies, ZBH has consistently introduced groundbreaking orthopedic solutions that have become industry standards, such as the first-ever metallic hip joint and the highly successful Persona® knee system.
As a global corporation, ZBH not only prioritizes its patients and healthcare providers but also its employees and shareholders. It strives to maintain a culture that respects and appreciates diversity, promotes employee engagement and well-being, and cultivates talent development.
Despite challenges posed by the changing regulatory landscape and competitive pressures in the medical device industry, ZBH continues to achieve solid financial performance. It does this by capitalizing on market opportunities, maintaining operational excellence, optimizing its product portfolio, and investing in strategic growth initiatives.
Zimmer Biomet's commitment to making a difference in people's lives is reflected not only by its product offerings but also by their strategic philanthropy and community engagement programs. ZBH takes a proactive approach to corporate social responsibility, driving sustainable practices in its operations, promoting health and safety, and actively supporting the communities where it operates.
Underpinning the success of ZBH is its enduring commitment to quality, integrity, and responsiveness — values that are embedded in its culture and reflected in its day-to-day operations. For nearly a century, Zimmer Biomet Holdings, Inc. has stood as a testament to resilience, innovation, and the enduring power of improving human health.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Edwards Lifesciences (NYSE:EW) has received a "Moderate Buy" rating from analysts, with an average target price of $100.27, suggesting an upside from its current share price of $86.39. The company recently surpassed quarterly earnings and revenue expectations and has significant institutional ownership. Despite some insider selling, analysts maintain a positive outlook, with several firms reiterating "buy" or "outperform" ratings and increasing price targets.
The global minimally invasive robotic surgical system market is projected to reach $18.15 billion by 2030, growing from $8.9 billion in 2025 due to increased precision, patient outcomes, and adoption in outpatient facilities. Key growth drivers include improved reimbursement, precision medicine, and demand for minimally invasive procedures. Product innovation and strategic acquisitions by major players like Intuitive Surgical, Johnson & Johnson, and Medtronic are strengthening the market, with North America currently the largest regional market and Asia-Pacific expected to be the fastest-growing.
Nykredit A/S recently acquired 37,377 shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH), establishing a new position valued at approximately $3.22 million. Institutional investors collectively own 88.89% of the company, and analysts have a "Hold" rating with a consensus price target of $103.00. Zimmer Biomet reported strong quarterly earnings, exceeding expectations with $2.07 adjusted EPS and $2.18 billion in revenue, and declared a quarterly dividend of $0.24 per share.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has received a consensus "Hold" rating from 22 brokerages, with an average 12-month price target of $103.00. The company recently exceeded quarterly expectations, reporting $2.07 in adjusted EPS and $2.18 billion in revenue, and has declared a quarterly dividend of $0.24 per share. Insider transactions show recent sales by Kevin R. Thornal and Chad F. Phipps, while institutional investors own a significant 88.89% of the stock.
Intuitive Surgical (ISRG) is targeting Ambulatory Surgery Centers (ASCs) as a key growth area for its robotic-surgery platforms, particularly with its refurbished XiR models. This strategy aims to broaden its customer base by offering lower-cost entry points into robotic surgery. Other companies like Stryker (SYK) and Zimmer Biomet (ZBH) are also focusing on the ASC market with their respective technologies and portfolios.
Zimmer Biomet announced it will showcase its complete shoulder solutions, including the updated ROSA Shoulder System and Signature Vision, at the 16th International Congress of Shoulder and Elbow Surgery (ICSES 2026). These technologies aim to provide surgeons with flexibility and precision for personalized shoulder care, addressing various clinical considerations. The offerings include robotic-assisted surgery, mixed reality navigation, pre-operative planning software, and a range of implant systems for both anatomic and reverse arthroplasty.
Bank of America Corp DE has acquired a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH), purchasing over 2.1 million shares valued at approximately $187.48 million in the second quarter. This move makes Bank of America Corp DE one of several institutional investors increasing their stakes in the medical equipment provider. Despite insider stock sales and a recent dip in share price, analysts maintain a "Hold" rating for Zimmer Biomet, with the company also announcing a quarterly dividend.